Pharmaceutical Quality Control Labs (7/93)
药品质量控制实验室（7/93）
传单英文GUIDE TO INSPECTIONS OF PHARMACEUTICAL QUALITY CONTROL LABORATORIES
autotestballoon药品质量控制实验室检查指南
Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any rights, privileges, benefits, or immunities for or on any person(s).
注：本文件是FDA调查员和其他人员的参考材料。该文件并没绑定FDA，也没授予任何人任何权利、特权或豁免权。温泉英语
1.INTRODUCTION
实业有限公司英文
1、简介
The pharmaceutical quality control laboratory rves one of the most important functions in pharmaceutical production and control.
deep throat药品质量控制实验室在药品生产与控制的过程当中，扮演着极其重要的角色。
A significant portion of the CGMP regulations (21 CFR 211) pertain to the quality control laboratory and product testing.
CGMP当中，有相当一部分规则是关于质量控制实验室及产品检测的。
Similar concepts apply to bulk drugs.
同样的概念也适用于原辅料。
This inspection guide supplements other inspectional information contained in other agency inspectional guidance documents.
该检查指南补充其他机构信息库中的指导文件。
For example, Compliance Program 7346.832 requiring pre-approval NDA/ANDA inspections contains general instructions to conduct product specific NDA/ANDA inspection audits to measure compliance with the applications and CGMP requirements.
例如，合则计划7346.832需要预先核准NDA/ANDA检查所包含的一般性指令，并以此来指导、衡量产品的具体NDA/ANDA检查程序是否符合CGMP的要求。
moonwalkThis includes pharmaceutical laboratories ud for in-process and finished product testing.
这包括用于生产的制药实验室与终产品的测试。
2.OBJECTIVE
2、目的
The specific objective will be spelled out prior to the inspection.
在检查之前，具体的目标就应该阐述清楚。
The laboratory inspection may be limited to specific issues, or the inspection may encompass a comprehensive evaluation of the laboratory's compliance with CGMP's.
实验室检查可以仅限于具体问题或者围绕CGMP中实验室应符合的综合评价展开。
As a minimum, each pharmaceutical quality control laboratory should receive a comprehensive GMP evaluation each two years as part of the statutory inspection obligation.
作为最低要求，每个药品质量控制实验室都应执行自己的法定检验义务，即每两年都应该接受一次全面的GMP评估。
In general the inspections may include
年复一年的意思
-- the specific methodology which will be ud to test a new product
-- a complete asssment of laboratory's conformance with GMP's
-- a specific aspect of laboratory operations
通常这个检查应该包括以下几点：
--用于测试一个新产品的特定方法
--实验室是否符合GMP的全面评估
九月英文缩写--一种特定的实验室操作
--------------------------------------------------------陈淑贤
3. INSPECTION PREPARATION
FDA Inspection Guides are bad on the team inspection approach and our inspection of a laboratory is consistent with this concept. As part of our effort to achieve uniformity and consistency in laboratory inspections, we expect that complex, highly technical and specialized testing equipment, procedures and data manipulations, as well as scientific laboratory operations will be evaluated by an experienced laboratory analyst with specialized knowledge in such matters.
District management makes the final decision regarding the assignment of personnel to inspections. Nevertheless, we expect investigators, analysts and others to work as teams and to advi management when additional experti is required to complete a meaningful inspection.
检查人员的委派由地区主管部门确定，然而我们希望，调查人员、分析人员和其他人员能组成—个检查组，并在需要时为了完成—项有意义的检查，可建议主管部门增加有关方面的专家。
Team members participating in a pre-approval inspection must read and be familiar with Compliance Program 7346.832, Pre-Approval Inspections/Investigations. Relevant ctions of the NDA or ANDA should be reviewed prior to the inspection; but if the application is not available from any other source, this review will have to be conducted using the company's copy of the application.
参加新药审批前检查的小组成员必须阅读并熟悉7346·832号文件即审批前检查或调查文件的内容。检查前应当审查新药申请或简略的新药申请的有关部分，如果该申请书不能从别
的来源得到，可对由公司提供的副本进行审查。
咖啡磨
Team members should meet, if possible, prior to the inspection to discuss the approach to the inspection, to define the roles of the team members, and to establish goals for completion of the assignment. Responsibilities for development of all reports should also be established prior to the inspection. This includes the preparation of the FDA 483.
如果可能的话，小组成员在检查之前就应当集中，以讨论检查方法，明确每位组员的角色，并确定目标以完成委派的任务。检查前还要确定负责起草各报告，包括准备FDA483文件的责任。
The Center for Drug Evaluation and Rearch (CDER) may have issued deficiency letters listing problems that the sponsor must correct prior to the approval of NDA/ANDA's and supplements. The inspection team is expected to review such letters on file at the district office, and they are expected to ask the plant for access to such letters. The team should evaluate the replies to the letters to assure that the data are accurate and authentic. Complete the inspection even though there has been no respon to the lett
ers or when the respon is judged inadequate.
